Ductal Carcinoma in situ: Overview and Updates
-
Upload
tucson-symposium -
Category
Health & Medicine
-
view
856 -
download
0
description
Transcript of Ductal Carcinoma in situ: Overview and Updates
![Page 1: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/1.jpg)
Ductal Carcinoma In Situ (DCIS)of the Human Breast
Overview and Updates
D. Craig Allred, MD
![Page 2: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/2.jpg)
NormalTDLU
EarlyExpansion of
TDLU by DCIS
CompleteExpansion of
TDLU by DCIS
Look Like Ducts “Ductal” Carcinoma In Situ
Definition of DCISBreast epithelial cells that have become "cancerous" but still reside
in their normal place inside the ducts and lobules.
![Page 3: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/3.jpg)
IBC
TDLU
ADHCCHDCIS
ALH LCIS
Time (decades in most cases)
Immediate precursor of invasive breast cancer
Importance of DCIS
TDLU
ADHCCHDCIS
ALH LCIS
Time (decades in most cases)
Late stage in breast cancer evolution
![Page 4: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/4.jpg)
DCIS is the Immediate Precursor of Invasive Breast Cancer (IBC)
![Page 5: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/5.jpg)
Historical Perspective of Invasive Breast Cancer
Ancient
Greece
DarkAges
MiddleAges
Renaissance
Today
Today
1600 BCEdwin Smith
PapyrusEgypt
Historical Perspective of DCIS
Early 1900sFirst Realized DCIS ≠
IBC2-3% all Breast Cancer
Tx = Radical Mastectomy (Cure)
Major Milestones Since:
· DCIS = Precursor of IBCNeeds Detection and Therapy
Screening MammographyDCIS = 20-30% all Breast Cancer
Lumpectomy + Adjuvant Rad ± Tam
Radical Mastectomy
![Page 6: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/6.jpg)
Natural History of DCIS
DCIS(Non-Lethal)
IBC(Potentially Lethal)
TDLU
ADHCCHDCIS
IBC
ALH LCIS
Time (decades in most cases)
TDLU
ADHCCHDCIS
IBC
ALH LCIS
Time (decades in most cases)
Overall Proportion Unknown
≥ 30-40% over 30 yearsJAMA 239:1863, 1978Cancer 46:919, 1980Cancer 49:751, 1982
Sem Diag Pathol 11:223, 1994
Absolute Proportion Too High
All IBCs from undetected DCIS
![Page 7: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/7.jpg)
Classification of DCIS
Comedo Cribriform Solid
PapillaryMicropapillary
Subtypes of DCIS based on gross appearance and predominant microscopic growth pattern
![Page 8: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/8.jpg)
Classification of DCISSubtypes of DCIS based on gross appearance and predominant microscopic growth pattern
Problem = Intra-Tumor Diversity
Solid/Comedo
Cribriform
≥50% DCIS with >1 pattern
Clin Cancer Res 14:339, 2008
![Page 9: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/9.jpg)
Classification of DCIS
Histological Grade:The Degree that Tumor
Resembles Normal
Histological Scoring and Grading of DCIS
Based on Scarff-Bloom-Richardson method of grading IBCClin Cancer Res 14:339, 2008
210 - 75%
intermediate1 - 2
10 - 50%
Score
1> 75%
low< 1
< 10%
3< 10%high> 2
> 50%
Microscopic FeatureA. Glands/papillaeB. Nuclear gradeC. Mitotic rateD. Central necrosis
S= total score (range 4-12)Grade 1 = 4 -7 points (well differentiated)Grade 2 = 8-9 points (intermediate differentiated)Grade 3 = 10-12 points (poorly differentiated)
A=1B=1C=1D=1Total=4Grade =1
A=2B=2C=2D=2Total=8Grade =2
A=3B=3C=3D=3Total=12Grade =3
![Page 10: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/10.jpg)
Classification of DCIS
Histological Grade:The Degree that Tumor
Resembles Normal
Problem = Intra-Tumor Diversity
Grade 3
Grade 1≥50% DCIS
with >1 GradeClin Cancer Res 14:339, 2008
![Page 11: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/11.jpg)
Classification of DCISBiological Features
Standard Prognostic Biomarkers
Histological Score (Modified SBR; Clin Cancer Res 14:339, 2008)
45
67
89
1011
120
Perc
ent
102030405060708090
100
N=200% ER+% PgR+
% p53+% HER2+
% Cases
Pure DCIS
avg %Ki67
WellDifferentiated
PoorlyDifferentiated
45
67
89
1011
12
N=200
56
78
9
N=200
IBC DCIS (+IBC)
34
DCIS IBC
![Page 12: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/12.jpg)
From: Solin, et al: J Clin Oncol 14:754, 1996.
Histological Grade and Standard Biomarkers in DCIS are Related to Rate but not Fate of Progressing to IBC.
![Page 13: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/13.jpg)
LuminalER/PR+GATA3+ERBB2-CK18+Other...
BasalERBB2-ER/PR-CK5+Other…
Mixed
ERBB2ERBB2+ER/PR-GRB7+Other...
Sorlie et al. PNAS 98:10869, 2001
DCIS IBC
Classification of DCISBiological Features
Intrinsic Molecular Subtypes
ERBB2Basal
MixedLuminal
DCISAllred et al. Clin Cancer Res 14:339, 2008
IBC
![Page 14: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/14.jpg)
Grade 1 Grade 2 Grade 3
Ca
se #
020
Ca
se #
012
29.2% 22.5% 2.5%30.0%
9.2%6.6%
30% 60% 10%
10% 85% 5%
Diversity of Histological (Nuclear) Grade Within Cases of DCIS (n=120)
Allred et al. Clin Cancer Res 2008
![Page 15: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/15.jpg)
Category1. No Diversity2. Grade3. Grade + Biol
% Cases51.8%48.2%13.4%
Diversity of Histological Grade and Biological Characteristics Within Cases (n=112)(ER, GATA3, Her2, CK5, CK18 and p53)
(Allred et al. Clin Cancer Res, 2008)
(1 vs. 2 vs. 3)
p=0.0016
% p53+13.8%40.5%45.5%
Exa
mpl
e: C
ase
10
6
H&E
H&E ER=7/8
ER=5/8
Her2=0/8
Her2=6/8 p53=6/8
p53=0/8
Grade 1(60%)
Grade 2(40%)
p=0.2833
% ER+70.7%60.8%57.6%
p=0.8296
% Her2+39.7%39.2%57.6%
![Page 16: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/16.jpg)
Diversity of Histological Grade and Intrinsic
Subtypes Within Cases of DCIS (n=112)(Allred et al. Clin Cancer Res, 2008)
Luminal ALuminal B
Basal
ERBB2
Different SubtypesSame Subtype
73% (11/15) of DCIS with diversity of histological (nuclear) grade and biomarkers
also showed diversity of intrinsic subtypes of nearly all possible combinations
LumA + erbB2 = 4 casesLumA + Basal = 1 caseLumA + LumB = 3 casesLumB + erbB2 = 2 casesBasal + erbB2 = 1 case
Cancer Stem Cell Conundrum
![Page 17: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/17.jpg)
DCIS(Non-Lethal)
IBC(Potentially Lethal)
TDLU
ADHCCHDCIS
IBC
ALH LCIS
Time (decades in most cases)
TDLU
ADHCCHDCIS
IBC
ALH LCIS
Time (decades in most cases)
DCIS ≠ IBC Regarding Invasion
Tumor Epithelial Cells Very SimilarMolec Cancer Res 1:362, 2003
PNAS 100:5974, 2003
Stromal Cells Very Different
Cancer Cell 6:17, 2004
![Page 18: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/18.jpg)
Genetic Differences DCIS vs. IBC
July, 2012
5 Cohorts DCIS vs. IBC54 samples each type50% LCM microdissectedAffymetrix microarrays
![Page 19: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/19.jpg)
Supervised Comparisons≥ 2 Fold; p < 0.05
472 Genes ≥ 1 Group This Study74 Genes ≥ 2 Groups This Study
Meta-analysis:69% Overlap with ≥1 of
all Previous Microarry StudiesAverage = 3.8 Studies/Gene
Range = 3 to 7 Studies
IBC > DCIS (n=42)Candidate Promotersof Tumor Progression
![Page 20: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/20.jpg)
DCIS > IBC (n=32)Candidate Suppressorsof Tumor Progression
Supervised Comparisons≥ 2 Fold; p < 0.05
472 Genes ≥1 Group This Study74 Genes ≥2 Groups This Study
Meta-analysis:38% Overlap with ≥1 of
all Previous Microarry StudiesAverage = 3.8 Studies/Gene
Range = 3 to 5 Studies
![Page 21: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/21.jpg)
Gene Expression Signature (n=74)DCIS vs. IBC
96% Correct Classification Study Samples
Hierarchical Clustering74-Gene Signature
(avg = 34/74 per group)
DCISIBC
![Page 22: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/22.jpg)
Gene Expression Signature (n=74)DCIS vs. IBC
95% Correct Classification Samples in 3 Independent Studies
DCISIBC
![Page 23: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/23.jpg)
Ontologies and Pathways Associated with the Progression of DCIS to IBC
Adjusted p-value
![Page 24: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/24.jpg)
Ontologies and Pathways in Tumor Epithelium vs.Stroma
EMT+
![Page 25: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/25.jpg)
Functional StudiesMammary Intraductal DCIS (MIND) Xenografts
(Behbod et al. Breast Cancer Res, 2009)
DCIS
IBC
DCIS.COM shCSTA-A9
DCIS.COM shCSTA-A9
![Page 26: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/26.jpg)
Functional StudiesHuman DCIS Cell Lines
Cell Line1. DCIS.COM2. DCIS.SUM.2253. DCIS.FSK-H74. hDCIS.015. hDCIS.026. hDCIS.037. hDCIS.048. hTDLU.019. hCCH.0110.hCCH.02
Max Pass #
>100>100
55>100
117
16131510
Keratin IHC+++++
++++++++++++++++++++++++
MIND Xenografts ≤10 WksNone
10%30%30%20%ndndndndndnd
DCIS60%70%70%60%ndndndndndnd
IBC30%0%0%
20%ndndndndndnd
1 2 3 4 5
6 7 8 9 10
![Page 27: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/27.jpg)
Knock Down (shRNAi) “Suppressors”Predict Increased Tumor Progression
1. I-A7 (hairpin)2. I-A9 (hairpin)3. I-D4 (hairpin)4. RFP-1 (control)5. RFP-2 (control)6. DCIS.COM-CBRz (control)
1 2 3 4 5 6
b-Actin
CSTA
Western Blot
3 of 3 hairpinssignificantly decrease protein
expression in DCIS.COM(1A7>IA9>1D4)
Real-time PCR
3 of 3 hairpinssignificantly decrease RNA
expression in DCIS.COM(1A9>1A7>1D4)
complete knockdown
DCIS.COM Transduced with CSTA shRNAi (n=3)
![Page 28: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/28.jpg)
Effects of Knocking
Down “Suppressors
” In Vivo(DCIS.COM)
Normally Suppress Invasion:
CSTA (Cystatin A)DST (Dystonin)
FAT1 (Procadherin)TMEM45A (Transmembrane
Protein 45A)
![Page 29: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/29.jpg)
Validation in Additional DCIS Cell Lines
NormallySuppress Invasion:
CSTADSTFAT1
![Page 30: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/30.jpg)
Validation of CSTA at Protein Levelby IHC in Human Breast Tissue
DCIS
A B
F
C D
E
TDLU
DCIS
DCIS
IBC
IBC
CCH
TDLU
TDLU CCH DCIS IBCCSTA Pos 96% 95% 58% 26%
#Cases 27 40 92 228
P <0.001
Normally Expressedin Myoepithelial Cells
Frequently Mislocalizedto Luminal Cells in DCIS
Significantly Reducedin IBC vs. DCIS
![Page 31: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/31.jpg)
DCIS.COM.shCSTA.1A7 MIND Xenografts
IHC for p63(human and mouse specific)
IHC for Vimentin(human specific)
Human DCIS Cell Lines are Pluripotential(Myoepithelial and Luminal)
MECs
MECs
LUMLUM
![Page 32: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/32.jpg)
pB-pu CILP-pu FAP-pu0.0
20.0
40.0
60.0
80.0
100.0
120.0
> 205 - 200 - 5none
DCIS.COM
Promote Invasion:CILP (Cartilage Intermediate Filament
Protein)FAP (Fibroblast Activation Protein Alpha)
Overexpress (cDNA) “Promoters”Predict Increased Tumor Progression
![Page 33: Ductal Carcinoma in situ: Overview and Updates](https://reader038.fdocuments.us/reader038/viewer/2022103109/54559379af795989638b8e42/html5/thumbnails/33.jpg)
Improved detection, diagnosis, and surgery (lumpectomy) of DCIS through targeted imaging based on molecular features specific for DCIS vs. IBC.
By understanding more about DCIS we can significantly decrease the incidence of IBC (at least 10%) during the next decade by:
Improved prognostication, therapy, and prevention of DCIS based on targeting molecular features regulating the progression DCIS to IBC.